James Harris, MD
Allergy & Immunology · South Bend, INNPI 1275523722
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by GSK at 39.3% of the total. Reporting peaked in 2023 at $405 and has fallen 69.5% since, to $124 in 2025. That places this record below the midpoint for allergy & immunology clinicians in IN, where the typical reported total is $4,393.
Across 52 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$515
- Genentech USA, Inc.$190
- Regeneron Healthcare Solutions, Inc.$163
- Pfizer$136
- Biohaven Pharmaceuticals, Inc.$61
- AbbVie$46
- plus $199 from 10 others
Across 165 payments — averaging $9791.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$384K
- Johnson & Johnson$356K
- Pfizer$318K
- Janssen Research & Development, LLC$216K
- Grifols Therapeutics LLC$166K
- Sanofi Pasteur Inc.$66K
- plus $109K from 7 others
Across 7 payments — averaging $15,622 each. An ownership or investment interest held by the physician or an immediate family member.
- Digital Diagnostics Inc.$109K
What the payments were for
- Food & beverage$1,311100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $515 |
| Genentech USA, Inc. | 9 | $190 |
| Regeneron Healthcare Solutions, Inc. | 9 | $163 |
| Pfizer | 2 | $136 |
| Biohaven Pharmaceuticals, Inc. | 1 | $61 |
| AbbVie | 2 | $46 |
| AstraZeneca | 2 | $45 |
| Biocryst US Sales Co., LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Zimmer Biomet | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| Alk-abello, Inc | 1 | $13 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$370
- NURTEC ODT$124
How this compares
$1,311 in reported general payments places this provider in the 25th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $80,277 |
| TezspireTezepelumab-Ekko | 15 | $63,818 |
| NucalaMepolizumab | 11 | $47,110 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $37,974 |
| Cromolyn Sodium | 20 | $23,016 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $15,843 |
| Spiriva RespimatTiotropium Bromide | 13 | $12,221 |
| Methscopolamine Bromide | 33 | $7,843 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $5,246 |
| Hydroxyzine Hcl | 212 | $5,117 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $4,418 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,646 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $3,429 |
| Ipratropium Bromide | 104 | $2,482 |
| Zafirlukast | 27 | $2,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $515 | $169,007175 claims |
| AstraZenecaTezspire, Symbicort | $45 | $79,66161 claims |
| Boehringer IngelheimSpiriva Respimat | $14 | $12,22113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in South Bend
- Sohaib AleemSouth Bend$4K
- Christina BarnesSouth Bend$2K
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Pooja PatelMerrillville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.